| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 60.1 | 41.2 | 47.1 |
| Other income | 0.2 | 0.1 | 0.4 |
| Total income | 60.3 | 41.3 | 47.6 |
| Profit before exceptional items & tax | 5.3 | 3.4 | 8.6 |
| Profit before tax | 5.3 | 3.4 | 8.6 |
| Net profit | 3.3 | 2.4 | 6.1 |
| Operating margin | 8.8% | 8.2% | 18.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.90% |
|---|---|
| Net profit, quarter on quarter | +37.50% |
| Revenue, year on year | +27.60% |
NSE results filing, NSE: SOTAC. Figures extracted from the filing.
Sotac Pharmaceuticals Limited: key numbers
- Share price
- ₹90.05
- Market cap
- ₹99.51 Cr
- Revenue (annual)
- ₹101.2 Cr
- Net profit (annual)
- ₹6.29 Cr
- P/E (TTM)
- 15.8×Sector 47.4×
- Promoter holding
- 72.85%
- FII holding
- 16.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sotac Pharmaceuticals Limited
All →Sotac Pharmaceuticals Dividend
Sotac Pharmaceuticals Limited has announced a record date of September 23, 2026, for the payment of a final dividend of Rs. 0.20 per share.
Sotac Pharmaceuticals Annual General Meeting
Sotac Pharmaceuticals Limited issued the notice for its 11th Annual General Meeting on September 30, 2026. Ordinary and special business will be transacted.
Sotac Pharmaceuticals Board Meeting Outcome
Sotac Pharmaceuticals' board approved the 11th AGM for September 30, 2026, and recommended a dividend of Rs. 0.20 per share.
Sotac Pharmaceuticals Bags ₹0.98 Cr Order
Sotac Pharmaceuticals received a purchase order from Intas Pharmaceuticals Limited for finished pharmaceutical formulations. The order is valued at ₹0.98 Crore.
- Value
- ₹0.98 Cr
- Execution
- September 05, 2026 to November 05, 2026
Sotac Pharmaceuticals Dividend
Sotac Pharmaceuticals recommended a final dividend of ₹0.20 per equity share for FY 2025-26. The distribution awaits shareholder approval at the upcoming AGM.
Sotac Pharmaceuticals Financial Results
Sotac Pharmaceuticals reported audited FY26 results and proposed a Rs. 0.20 per share dividend. Consolidated annual revenue reached ₹101.24 Crore with a net profit of ₹5.77 Crore.
- Value
- ₹0.22 Cr